Linagliptin; Metformin Hydrochloride is used for managing type 2 diabetes with renal impairment and inadequate glycemic control. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Jentadueto on Jan 30, 2012. Another drug containing Linagliptin; Metformin Hydrochloride is Jentadueto Xr. 3 different companies have introduced drugs containing Linagliptin; Metformin Hydrochloride.

Linagliptin; Metformin Hydrochloride Patents

Given below is the list of patents protecting Linagliptin; Metformin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Jentadueto Xr	US9555001 (Pediatric)	Pharmaceutical composition and uses thereof	Sep 06, 2033	Boehringer Ingelheim
Jentadueto Xr	US9555001	Pharmaceutical composition and uses thereof	Mar 06, 2033	Boehringer Ingelheim
Jentadueto	US8846695 (Pediatric)	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Dec 04, 2030	Boehringer Ingelheim
Jentadueto	US9155705 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Nov 21, 2030	Boehringer Ingelheim
Jentadueto Xr	US9155705 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Nov 21, 2030	Boehringer Ingelheim
Jentadueto	US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Jun 04, 2030	Boehringer Ingelheim
Jentadueto Xr	US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Jun 04, 2030	Boehringer Ingelheim
Jentadueto	US9155705	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May 21, 2030	Boehringer Ingelheim
Jentadueto Xr	US9155705	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May 21, 2030	Boehringer Ingelheim
Jentadueto	US11911388	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug	Apr 10, 2030	Boehringer Ingelheim
Jentadueto Xr	US11911388	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug	Apr 10, 2030	Boehringer Ingelheim
Jentadueto	US10022379 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct 02, 2029	Boehringer Ingelheim
Jentadueto	US10973827 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct 02, 2029	Boehringer Ingelheim
Jentadueto	US9415016 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct 02, 2029	Boehringer Ingelheim
Jentadueto Xr	US10022379 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct 02, 2029	Boehringer Ingelheim
Jentadueto Xr	US9415016 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct 02, 2029	Boehringer Ingelheim
Jentadueto	US10022379	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr 02, 2029	Boehringer Ingelheim
Jentadueto	US10973827	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr 02, 2029	Boehringer Ingelheim
Jentadueto	US9415016	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr 02, 2029	Boehringer Ingelheim
Jentadueto Xr	US10022379	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr 02, 2029	Boehringer Ingelheim
Jentadueto Xr	US9415016	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr 02, 2029	Boehringer Ingelheim
Jentadueto	US8673927 (Pediatric)	Uses of DPP-IV inhibitors	Nov 04, 2027	Boehringer Ingelheim
Jentadueto Xr	US8673927 (Pediatric)	Uses of DPP-IV inhibitors	Nov 04, 2027	Boehringer Ingelheim
Jentadueto Xr	US9173859 (Pediatric)	Uses of DPP IV inhibitors	Nov 04, 2027	Boehringer Ingelheim
Jentadueto	US8673927	Uses of DPP-IV inhibitors	May 04, 2027	Boehringer Ingelheim
Jentadueto	US9173859	Uses of DPP IV inhibitors	May 04, 2027	Boehringer Ingelheim
Jentadueto Xr	US8673927	Uses of DPP-IV inhibitors	May 04, 2027	Boehringer Ingelheim
Jentadueto Xr	US9173859	Uses of DPP IV inhibitors	May 04, 2027	Boehringer Ingelheim
Jentadueto	US8883805 (Pediatric)	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	May 26, 2026	Boehringer Ingelheim
Jentadueto Xr	US8883805 (Pediatric)	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	May 26, 2026	Boehringer Ingelheim
Jentadueto	US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov 26, 2025	Boehringer Ingelheim
Jentadueto Xr	US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov 26, 2025	Boehringer Ingelheim
Jentadueto	US7407955 (Pediatric)	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Nov 02, 2025	Boehringer Ingelheim
Jentadueto Xr	US7407955 (Pediatric)	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Nov 02, 2025	Boehringer Ingelheim
Jentadueto	US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May 02, 2025 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May 02, 2025 (Expired)	Boehringer Ingelheim
Jentadueto	US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug 12, 2023 (Expired)	Boehringer Ingelheim
Jentadueto	US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug 12, 2023 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug 12, 2023 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug 12, 2023 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US6488962	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms	Jun 20, 2020 (Expired)	Boehringer Ingelheim
Jentadueto	US6890898	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Jentadueto	US7078381	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Jentadueto	US7459428	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US6890898	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US7078381	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US7459428	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Boehringer Ingelheim
Jentadueto	US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	Apr 24, 2017 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	Apr 24, 2017 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US6340475	Extending the duration of drug release within the stomach during the fed mode	Sep 19, 2016 (Expired)	Boehringer Ingelheim
Jentadueto Xr	US6635280	Extending the duration of drug release within the stomach during the fed mode	Sep 19, 2016 (Expired)	Boehringer Ingelheim

Add above patents to watchlist

Linagliptin; Metformin Hydrochloride's Family Patents

Full family tree

Linagliptin; Metformin Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Linagliptin; Metformin Hydrochloride. The first generic version for Linagliptin; Metformin Hydrochloride was by Sunshine Lake Pharma Co Ltd and was approved on Aug 30, 2021. And the latest generic version is by Zydus Pharmaceuticals Usa Inc and was approved on Mar 30, 2023.

Given below is the list of companies who have filed for Linagliptin; Metformin Hydrochloride generic, along with the locations of their manufacturing plants worldwide.